Abstract: The present invention provides novel uses of compounds of general formula I: ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R.sup.2 and R.sup.3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of atrophy of skin and/or mucous membranes.
Type:
Grant
Filed:
July 11, 1996
Date of Patent:
May 5, 1998
Assignee:
Novo Nordisk A/S
Inventors:
Niels Korsgaard, James Robertson Piggott, Virender Mohan Labroo, Steven Bain
Abstract: A glucose oxidase obtained from a Cladosporium oxysporum strain, designated as CBS 163.94, characterized by a pH-optimum in he range pH 6-7, having more than 75% of maximum activity at pH 8, determined at 30.degree. C. with D-glucose as substrate.
Type:
Grant
Filed:
May 25, 1995
Date of Patent:
April 21, 1998
Assignee:
Novo Nordisk A/S
Inventors:
Karen M. Oxenb.o slashed.ll, Joan Qi Si, Jesper Aagaard
Abstract: The present invention relates to lipase and .alpha.-amylase variants, stabilized towards the inactiviation caused by peroxidase systems, in which variants a naturally occurring tryosine residue has been deleted, substituted with a different amino acid residue at one or more positions. The invention also relates to a method of stabilizing a lipase or an .alpha.-amylase towards the inactivation caused by the preoxidase systems, and detergent compositions comprising a lipase and/or .alpha.-amylase variant of the invention.
Type:
Grant
Filed:
June 15, 1995
Date of Patent:
March 24, 1998
Assignee:
Novo Nordisk A/S
Inventors:
Egon Nielsen, Grethe Rasmussen, Torben Halkier
Abstract: The present invention provides novel uses of compounds of general formula I ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); and R.sup.2 and R.sup.
Abstract: The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions.
Abstract: A pharmaceutical formulation comprising a growth hormone and Leu-His-Leu as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.
Type:
Grant
Filed:
January 13, 1995
Date of Patent:
January 6, 1998
Assignee:
Novo Nordisk A/S
Inventors:
Thorkild Christensen, Per Balschmidt, Hans Holmegaard S.o slashed.rensen, Ole Hvilsted Olsen, Lars Thim
Abstract: The present invention is related to a process for producing an active enzyme comprising fermenting the proform of the active enzyme in the present of a proteolytic enzyme different from the active enzyme and capable of converting the proenzyme into an active enzyme as well as to host cells, recombinant expression vectors and host cells suitable for use in the process.
Type:
Grant
Filed:
May 4, 1994
Date of Patent:
December 30, 1997
Assignees:
Novo Nordisk A/S, Novo Nordisk Biotech, Inc.
Inventors:
Sven Hastrup, Sven Branner, Birthe Ravn J.o slashed.rgensen, Tove Christensen, Birgitte Bojer J.o slashed.rgensen, Jeffrey R. Shuster, Mark Madden, Donna L. Moyer, Claus Fuglsang
Abstract: The present invention provides novel uses of compounds of general formula I ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifiuoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R.sup.2 and R.sup.3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of cerebral degenerative disorders.
Type:
Grant
Filed:
January 11, 1996
Date of Patent:
December 9, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Niels Korsgaard, Michael Shalmi, Birgitte Hjort Guldhammer
Abstract: A bacterial cell which in its genome carries an integrated non-replicative DNA construct comprising (1) a DNA sequence of interest, (2) a DNA sequence which is homologous with a region of the genome of the cell, and (3) an origin of replication, the DNA construct lacking a functional gene coding for a factor required to initiate replication from the origin of replication.
Abstract: The present invention relates to recombinant thermophilic host cells comprising a nucleic acid sequence encoding a heterologous protein, and a method of producing recombinant protein utilizing same. The recombinant hosts of the present invention provide a better morphology in tank fermentations than many known fungal host cells, such as Aspergillus, which morphology results in lower viscosity levels, and therefore improved productivity.
Abstract: The present invention relates to a novel metalloprotease obtainable from a fungus having increased proteolytic activity. Additionally, the invention related to isolated nucleic acid fragments encoding said metalloprotease as well as vectors, DNA constructs, and recombinant host cells comprising said nucleic acid fragments.
Type:
Grant
Filed:
May 17, 1995
Date of Patent:
November 25, 1997
Assignees:
Novo Nordisk A/S, Novo Nordisk Biotech, Inc.
Inventors:
Jeffrey R. Shuster, Mark Madden, Donna L. Moyer, Claus Fuglsang, Sven Branner
Abstract: Novel compounds of formula I ##STR1## wherein R.sup.1 is independently hydrogen, hydroxy, alkyl with 1 to 6 carbon atoms, acyloxy groups with 1 to 6 carbon atoms, alkyloxy with 1 to 6 carbon atoms or from 1 to 5 sugar moieties; and R.sup.2 is independently hydrogen, or alkyl with 1 to 6 carbon atoms. The compounds are producible by aerobic cultivation on suitable nutrient media under suitable conditions of a strain of the fungus Ascochyta sp., subsequent recovery of the active component from the fermentation medium, and optionally modifying the active compound to obtain a compound of the desired formula I. Disclosed is also microorganisms capable of producing said compounds, compositions containing said compounds, and the use of such compositions for controlling fungi in valuable crops, animals, including birds and mammals, and in the preservation of wood, paints and edible products.
Type:
Grant
Filed:
April 24, 1995
Date of Patent:
September 30, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Ruby Illum Nielsen, Frank Winther Rasmussen
Abstract: Addition of a water-soluble polyelectrolyte (i.e. an anionic or cationic polymer) significantly increases the hydrolysis rate of esters in the presence of lipases. The invention provides a process for hydrolysis of water-insoluble ester in the presence of a lipase characterized by the presence of a water-soluble polyelectrolyte. The invention also provides a method of increasing the rate of hydrolysis of water-insoluble ester in the presence of a lipase by incorporation of a water-soluble polyelectrolyte.
Abstract: The invention provides a series of crystalline salts of (S)-8-chloro-5-(5-bromo-2,3-dihydrobenzofuran-7-yl)-3-methyl-2,3,4,5-tetra hydro-1H-3-benzazepine-7-ol, their preparation and use as therapeutic agents.
Type:
Grant
Filed:
March 14, 1995
Date of Patent:
August 19, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Louis Brammer Hansen, Rolf Emil Amsler, Scott Eugene McGraw
Abstract: A pharmaceutical formulation comprising a growth hormone and leucine shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.
Abstract: Novel compounds of the general composition I, Lactate (1), Glycine (1), Valine (4), Isoleucine (1), pipecolic acid (1), Aspartic acid (1), Tyrosine (1), wherein each amino acid residue independently may occur in L- or D- form, and wherein the number in parenthesis indicates the number of occurrences of each moiety, and derivatives thereof are disclosed. The compounds are producible by aerobic cultivation on suitable nutrient media under suitable conditions of a strain of the fungus Curvularia sp., subsequent recovery of the active component from the fermentation medium, and optionally modifying the active compound to obtain a compound of the desired general composition. Disclosed are also microorganisms capable of producing said compounds, compositions containing said compounds, and the use of such compositions for controlling fungi in crops, and in the preservation of wood, paints, cosmetics, and edible products.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
August 5, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Jens Breinholt, Ruby Ione Nielsen, Georg Wilhelm Jensen
Abstract: The invention is directed to an isolated nucleic acid construct(s) comprising a nucleic acid sequence encoding an alkaline protease having a molecular weight of about 34 kD and is obtainable from a strain of Bacillus sp. Group I, as well as recombinant vectors and host cells comprising such constructs. Additionally, the invention is directed to a method for obtaining the protease. The invention is also directed to promoter and signal sequences derived from said alkaline protease as well as methods of using the promoter and signal sequences in the expression of heterologous nucleic acid sequences encoding heterologous proteins in bacteria.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
July 22, 1997
Assignees:
Novo Nordisk Biotech, Inc., Novo Nordisk A/S
Inventors:
Alan P. Sloma, Helle Outtrup, Claus Dambmann, Dorrit Anita Aaslyng
Abstract: Fungicidal compositions comprising compounds of the general formula III ##STR1## cyclo-[Pec-MeAsp-MeVal-Val-MeVal-MeIle-Gly-MeVal-TyrOMe-D-Lact] (III) wherein each amino acid residue and the lactate residue independently may occur in L- or D-form, and derivatives thereof in combination with other biocidal agents are disclosed. Said compositions may be used for controlling fungi in crops and in the preservation of wood, paints, cosmetics, and edible products.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
July 8, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Jens Breinholt, Ruby Ione Nielsen, Georg Wilhelm Jensen
Abstract: The invention is directed to compounds having general formula (I) or general formula (II). Compounds of formulae (I) or (II) have interesting antifungal activities and may, accordingly, be used as active ingredients in fungicidal compositions.